100 results
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
of Common Stock. We will bear all fees and expenses incident to our obligation to register the shares of Common Stock.
The Selling Stockholders may sell
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution
8-K
EX-10.2
k83h2rdxvkf
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-1.1
80qfez
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B3
wgeed19yo5jkx
29 Sep 23
Prospectus supplement
4:56pm
8-K
EX-10.1
rhkuqp7 9o3w
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-1.1
v2abn0v7lsdk
12 May 22
Entry into a Material Definitive Agreement
8:31am
424B3
sbjgv1kp6jjs
27 Dec 21
Prospectus supplement
5:01pm
8-K
EX-10.1
99oju3f
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-1.1
29qb36k
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
8-K
EX-1.1
fcv7xe
26 Jan 21
Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock
5:09pm
8-K
EX-10.1
y1yy t8o1l7yiq1c
17 Dec 20
Entry into a Material Definitive Agreement
4:05pm
424B3
dbndsn
4 Dec 20
Prospectus supplement
4:48pm